Antibody to tigit and use thereof

Abstract

The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.

1 . An antibody specifically binding to TIGIT (T-cell immunoreceptor with Ig and tyrosine-based inhibitory motif domains) or an antigen-binding fragment thereof, comprising:
 a heavy-chain CDR1 represented by SEQ ID NO: 3, 6, 9 or 12;   a heavy-chain CDR2 represented by SEQ ID NO: 4, 7 or 10;   a heavy-chain CDR3 represented by SEQ ID NO: 5, 8, 11 or 13;   a light-chain CDR1 represented by SEQ ID NO: 14, 17, 20, 23 or 25;   a light-chain CDR2 represented by SEQ ID NO: 15, 18, 21 or 26; and   a light-chain CDR3 represented by SEQ ID NO: 16, 19, 22, 24 or 27.   
     
     
         2 . The antibody or antigen-binding fragment thereof according to  claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:
 a heavy-chain CDR1 of SEQ ID NO: 3, a heavy-chain CDR2 of SEQ ID NO: 4, a heavy-chain CDR3 of SEQ ID NO: 5, a light-chain CDR1 of SEQ ID NO: 14, a light-chain CDR2 of SEQ ID NO: 15, and a light-chain CDR3 of SEQ ID NO: 16;   a heavy-chain CDR1 of SEQ ID NO: 6, a heavy-chain CDR2 of SEQ ID NO: 7, a heavy-chain CDR3 of SEQ ID NO: 8, a light-chain CDR1 of SEQ ID NO: 17, a light-chain CDR2 of SEQ ID NO: 18, and a light-chain CDR3 of SEQ ID NO: 19;   a heavy-chain CDR1 of SEQ ID NO: 9, a heavy-chain CDR2 of SEQ ID NO: 10, a heavy-chain CDR3 of SEQ ID NO: 11, a light-chain CDR1 of SEQ ID NO: 20, a light-chain CDR2 of SEQ ID NO: 21, and a light-chain CDR3 of SEQ ID NO: 22;   a heavy-chain CDR1 of SEQ ID NO: 9, a heavy-chain CDR2 of SEQ ID NO: 10, a heavy-chain CDR3 of SEQ ID NO: 11, a light-chain CDR1 of SEQ ID NO: 23, a light-chain CDR2 of SEQ ID NO: 21, and a light-chain CDR3 of SEQ ID NO: 24; or   a heavy-chain CDR1 of SEQ ID NO: 12, a heavy-chain CDR2 of SEQ ID NO: 10, a heavy-chain CDR3 of SEQ ID NO: 13, a light-chain CDR1 of SEQ ID NO: 25, a light-chain CDR2 of SEQ ID NO: 26, and a light-chain CDR3 of SEQ ID NO: 27.   
     
     
         3 . The antibody or antigen-binding fragment thereof according to  claim 1 , wherein the antibody or antigen-binding fragment thereof comprises at least one heavy-chain variable region selected from the group consisting of SEQ ID NOS: 28 to 32. 
     
     
         4 . The antibody or antigen-binding fragment thereof according to  claim 1 , wherein the antibody or antigen-binding fragment thereof comprises at least one light-chain variable region selected from the group consisting of SEQ ID NOS: 34 to 38. 
     
     
         5 . A nucleic acid encoding the antibody or antigen-binding fragment thereof according to  claim 1 . 
     
     
         6 . A vector comprising the nucleic acid according to  claim 5 . 
     
     
         7 . A cell transformed with the vector according to  claim 6 . 
     
     
         8 . A method of producing an antigen binding to TIGIT or an antigen-binding fragment thereof comprising:
 (a) culturing the cell according to  claim 7 ; and   (b) recovering an antibody or antigen-binding fragment thereof from the cultured cell.   
     
     
         9 . A composition for preventing or treating cancer comprising the antibody or antigen-binding fragment thereof according to  claim 1  as an active ingredient. 
     
     
         10 . A composition for preventing or treating cancer using the antibody or antigen-binding fragment thereof according to  claim 1  in combination with an anticancer therapy. 
     
     
         11 . A composition for preventing or treating cancer using the antibody or antigen-binding fragment thereof according to  claim 1  in combination with an immune checkpoint inhibitor. 
     
     
         12 . The composition according to  claim 11 , wherein the immune checkpoint inhibitor targets PD-1.